Latest Neoadjuvant chemotherapy Stories
A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn't effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer.
A new study shows that magnetic resonance imaging (MRI), when compared with clinical examination, can actually give an earlier indication of a breast tumor’s response to pre-surgical chemotherapy.
Whether chemotherapy is given before or after breast-conserving therapy (BCT) does not have an impact on long-term local-regional outcomes, suggesting treatment success is due more to biologic factors than chemotherapy timing.
A new study has shown that magnetic resonance imaging (MRI) used to evaluate responses to pre-surgery (neo-adjuvant) chemotherapy or radiation may predict survival among patients with advanced rectal cancer.
Amid the controversy surrounding the Food and Drug Administration's ruling that Avastin should no longer be used to treat metastatic breast cancer, a new multinational Phase III clinical trial shows that Avastin significantly increased tumor response rates in breast cancer patients when given before surgery.
Researchers from Boston University School of Medicine (BUSM) have found that patients with node negative T3 and T4 non-small lung cancer who underwent chemotherapy before surgery had more than three times the survival rate than patients who only underwent surgery.
WASHINGTON, D.C., Nov. 4, 2010 /PRNewswire/ -- Dr.
SAN DIEGO, May 26 /PRNewswire/ -- In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy. PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion.
NEWPORT NEWS, Va., April 30 /PRNewswire/ -- A new study, presented at the American Society of Breast Surgeons Annual Meeting in Las Vegas, found that Breast-Specific Gamma Imaging (BSGI) is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy.
In research published this week in PLoS Medicine, JÃ¶rg Kleeff from Technische UniversitÃ¤t MÃ¼nchen, and colleagues suggest that patients with apparently locally non-resectable tumors should be included in neoadjuvant protocols.
- A woman chauffeur.
- A woman who operates an automobile.